|
TRIM44 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.65822910958013E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.95340427061797E-11 |
| Normal-vs-Stage2 |
2.91230000004639E-06 |
| Normal-vs-Stage3 |
5.57220936059366E-13 |
| Normal-vs-Stage4 |
3.51569995338252E-10 |
| Stage1-vs-Stage2 |
6.574200E-01 |
| Stage1-vs-Stage3 |
1.201410E-01 |
| Stage1-vs-Stage4 |
1.780640E-01 |
| Stage2-vs-Stage3 |
1.213400E-01 |
| Stage2-vs-Stage4 |
1.334770E-01 |
| Stage3-vs-Stage4 |
8.520400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.10751424592581E-13 |
| Normal-vs-AfricanAmerican |
6.41869999999933E-05 |
| Normal-vs-Asian |
5.95210003506708E-09 |
| Caucasian-vs-AfricanAmerican |
6.544800E-01 |
| Caucasian-vs-Asian |
5.239000E-01 |
| AfricanAmerican-vs-Asian |
3.806800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.64233079860787E-14 |
| Normal-vs-Female |
7.20024040390399E-12 |
| Male-vs-Female |
3.924100E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.12899994803217E-09 |
| Normal-vs-Age(41-60Yrs) |
1.84297022087776E-13 |
| Normal-vs-Age(61-80Yrs) |
6.42039754694679E-11 |
| Normal-vs-Age(81-100Yrs) |
4.352600E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.461350E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.693000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.035600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.165000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.149800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.910000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.917900E-02 |
| Classical-VS-Follicular |
3.394200E-01 |
| Classical-VS-Other |
7.988000E-02 |
| Classical-VS-Normal |
1.02390318446055E-11 |
| Tall-VS-Follicular |
3.073800E-01 |
| Tall-VS-Other |
2.836000E-01 |
| Tall-VS-Normal |
1.36139999273865E-09 |
| Follicular-VS-Other |
2.114800E-01 |
| Follicular-VS-Normal |
6.19939999335628E-09 |
| Other-VS-Normal |
1.170820E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
9.06830166513828E-13 |
| Normal-vs-N1 |
4.72450001343105E-09 |
| N0-vs-N1 |
4.106600E-01 |
|
|
